+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Alpha Glucosidase Inhibitors Market Research Report by Drug class, Constituent, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

  • PDF Icon

    Report

  • 137 Pages
  • January 2023
  • Region: United States
  • 360iResearch™
  • ID: 5721293
The United States Alpha Glucosidase Inhibitors Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Alpha Glucosidase Inhibitors Market.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Alpha Glucosidase Inhibitors Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Alpha Glucosidase Inhibitors Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Alpha Glucosidase Inhibitors Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Alpha Glucosidase Inhibitors Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Alpha Glucosidase Inhibitors Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug class, the market is studied across Acarbose (Precose), Miglitol (Glyset), and Voglibose.
  • Based on Constituent, the market is studied across Glucoamylase, Isomaltas, Maltase, and Sucrase.
  • Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Alpha Glucosidase Inhibitors Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Alpha Glucosidase Inhibitors Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Alpha Glucosidase Inhibitors Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Alpha Glucosidase Inhibitors Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Alpha Glucosidase Inhibitors Market, including Amneal Pharmaceuticals LLC, Bayer AG, BioVision Inc. by Abcam US Group Holdings Inc., East China Pharmaceutical by Huadong Pharmaceutical Co., Ltd., Empros Pharma AB, Lotus Pharmaceutical Co., Ltd., Merck KGaA, Novo Nordisk A/S, Straight Healthcare, Strides Arcolab Limited, and Takeda Pharmaceutical Co. Ltd..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Alpha Glucosidase Inhibitors Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Alpha Glucosidase Inhibitors Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Alpha Glucosidase Inhibitors Market?
4. What is the competitive strategic window for opportunities in the United States Alpha Glucosidase Inhibitors Market?
5. What are the technology trends and regulatory frameworks in the United States Alpha Glucosidase Inhibitors Market?
6. What is the market share of the leading vendors in the United States Alpha Glucosidase Inhibitors Market?
7. What modes and strategic moves are considered suitable for entering the United States Alpha Glucosidase Inhibitors Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of type 1 and type 2 diabetes
5.1.1.2. Growing awareness of benefits of alpha glucosidase inhibitors
5.1.2. Restraints
5.1.2.1. Availability of counterfeiter drugs
5.1.3. Opportunities
5.1.3.1. Increasing technological advancements on alpha glucosidase inhibitors
5.1.4. Challenges
5.1.4.1. Stringent rules and regulations for new product approvals
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Alpha Glucosidase Inhibitors Market, by Drug class
6.1. Introduction
6.2. Acarbose (Precose)
6.3. Miglitol (Glyset)
6.4. Voglibose

7. Alpha Glucosidase Inhibitors Market, by Constituent
7.1. Introduction
7.2. Glucoamylase
7.3. Isomaltas
7.4. Maltase
7.5. Sucrase

8. California Alpha Glucosidase Inhibitors Market
8.1. Introduction

9. Florida Alpha Glucosidase Inhibitors Market
9.1. Introduction

10. Illinois Alpha Glucosidase Inhibitors Market
10.1. Introduction

11. New York Alpha Glucosidase Inhibitors Market
11.1. Introduction

12. Ohio Alpha Glucosidase Inhibitors Market
12.1. Introduction

13. Pennsylvania Alpha Glucosidase Inhibitors Market
13.1. Introduction

14. Texas Alpha Glucosidase Inhibitors Market
14.1. Introduction

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Product Portfolio Analysis, By Key Player
15.5. Competitive Scenario
15.5.1. Merger & Acquisition
15.5.2. Agreement, Collaboration, & Partnership
15.5.3. New Product Launch & Enhancement
15.5.4. Investment & Funding
15.5.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. Amneal Pharmaceuticals LLC
16.2. Bayer AG
16.3. BioVision Inc. by Abcam US Group Holdings Inc.
16.4. East China Pharmaceutical by Huadong Pharmaceutical Co., Ltd.
16.5. Empros Pharma AB
16.6. Lotus Pharmaceutical Co., Ltd.
16.7. Merck KGaA
16.8. Novo Nordisk A/S
16.9. Straight Healthcare
16.10. Strides Arcolab Limited
16.11. Takeda Pharmaceutical Co. Ltd.

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET DYNAMICS
FIGURE 8. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG CLASS, 2030
FIGURE 12. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ACARBOSE (PRECOSE), 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MIGLITOL (GLYSET), 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY VOGLIBOSE, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET COMPETITIVE STRATEGIC WINDOW, BY CONSTITUENT, 2030
FIGURE 18. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY GLUCOAMYLASE, 2018-2030 (USD MILLION)
FIGURE 19. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ISOMALTAS, 2018-2030 (USD MILLION)
FIGURE 20. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MALTASE, 2018-2030 (USD MILLION)
FIGURE 21. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SUCRASE, 2018-2030 (USD MILLION)
FIGURE 22. CALIFORNIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 23. FLORIDA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 24. ILLINOIS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 25. NEW YORK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 26. OHIO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 27. PENNSYLVANIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 28. TEXAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 29. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 30. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 31. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ACARBOSE (PRECOSE), 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ACARBOSE (PRECOSE), BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MIGLITOL (GLYSET), 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MIGLITOL (GLYSET), BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY VOGLIBOSE, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY VOGLIBOSE, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY GLUCOAMYLASE, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY GLUCOAMYLASE, BY STATE, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ISOMALTAS, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ISOMALTAS, BY STATE, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MALTASE, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MALTASE, BY STATE, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SUCRASE, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SUCRASE, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. CALIFORNIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 22. CALIFORNIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. CALIFORNIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2018-2030 (USD MILLION)
TABLE 24. FLORIDA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 25. FLORIDA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. FLORIDA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2018-2030 (USD MILLION)
TABLE 27. ILLINOIS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 28. ILLINOIS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. ILLINOIS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2018-2030 (USD MILLION)
TABLE 30. NEW YORK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 31. NEW YORK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. NEW YORK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2018-2030 (USD MILLION)
TABLE 33. OHIO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 34. OHIO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. OHIO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2018-2030 (USD MILLION)
TABLE 36. PENNSYLVANIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 37. PENNSYLVANIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. PENNSYLVANIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2018-2030 (USD MILLION)
TABLE 39. TEXAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 40. TEXAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. TEXAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY CONSTITUENT, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 43. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 44. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 45. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 46. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 47. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 48. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET MERGER & ACQUISITION
TABLE 49. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 50. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 51. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET INVESTMENT & FUNDING
TABLE 52. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 53. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET: LICENSE & PRICING

Companies Mentioned

  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • BioVision Inc. by Abcam US Group Holdings Inc.
  • East China Pharmaceutical by Huadong Pharmaceutical Co., Ltd.
  • Empros Pharma AB
  • Lotus Pharmaceutical Co., Ltd.
  • Merck KGaA
  • Novo Nordisk A/S
  • Straight Healthcare
  • Strides Arcolab Limited
  • Takeda Pharmaceutical Co. Ltd.

Methodology

Loading
LOADING...